62
Views
9
CrossRef citations to date
0
Altmetric
Review

New avenues for second-line treatment of metastatic non-small-cell lung cancer

, , , , , , , , , , & show all
Pages 115-124 | Published online: 10 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Elena Galvani, Godefridus J Peters & Elisa Giovannetti. (2011) Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opinion on Investigational Drugs 20:10, pages 1343-1356.
Read now

Articles from other publishers (8)

Lindsay M. MortonGraça M. Dores, Margaret A. TuckerClara J. KimKenan Onel, Ethel S. GilbertJoseph F. FraumeniJrJrRochelle E. Curtis. (2013) Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 121:15, pages 2996-3004.
Crossref
Young-Min SonJoo-Young Roh, Eun-Kyung ChoJong-Rok Lee. (2011) Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel. Annals of Dermatology 23:Suppl 3, pages S314.
Crossref
Yanhong Gu, Wei Zhao, Fanyu Meng, Bingqian Qu, Xu Zhu, Yang Sun, Yongqian Shu & Qiang Xu. (2010) Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clinical Immunology 135:1, pages 55-62.
Crossref
Wolfram C.M. Dempke, Tamas Suto & Martin Reck. (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67:3, pages 257-274.
Crossref
Georgios S. Papaetis & Kostas N. Syrigos. (2009) Sunitinib. BioDrugs 23:6, pages 377-389.
Crossref
R.M. Eager, C.C. Cunningham, N. Senzer, D.A. Richards, R.N. Raju, B. Jones, M. Uprichard & J. Nemunaitis. (2009) Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer. Clinical Oncology 21:6, pages 464-472.
Crossref
António Araújo. (2009) Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827. Revista Portuguesa de Pneumologia (English Edition) 15:3, pages 560-566.
Crossref
. (2009) Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803-827. Revista Portuguesa de Pneumologia 15:3, pages 560-566.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.